NEW YORK (GenomeWeb News) – Celera reported after the close of the market on Tuesday that its fourth-quarter revenues rose 15 percent year over year, while the firm swung from a profit to a loss on increased SG&A spending.

The Alameda, Calif.-based personalized disease management products firm brought in revenues of $47.3 million for the three-month period ended Dec. 27, compared to revenue of $40.3 million for the three-month period ended Dec. 31, 2007.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.